Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer's Disease

• Egile Nagusiak: Ignazio Schino (Egilea), Mariangela Cantore (Egilea), Modesto de Candia (Egilea), Cosimo D. Altomare (Egilea), Catarina Maria (Egilea), João Barros (Egilea), Vasco Cachatra (Egilea), Patrícia Calado (Egilea), Karina Shimizu (Egilea), Adilson A. Freitas (Egilea), Maria C. Oliveira (Egilea), Maria J. Ferreira (Egilea), José N. C. Lopes (Egilea), Nicola A. Colabufo (Egilea), Amélia P. Rauter (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Alzheimer's Disease (AD) is characterized by a progressive cholinergic neurotransmission imbalance, with a decrease of acetylcholinesterase (AChE) activity followed by a significant increase of butyrylcholinesterase (BChE) in the later AD stages. BChE activity is also crucial for the developmen...